0
El Departamento de Salud y Servicios Humanos de EE. UU. (HHS), a través de la Administración de Alimentos y Medicamentos de EE. UU. (FDA), está poniendo en marcha una iniciativa para equiparar...
More >- INICIO
-
Genéricos
Novedades
- FDA approves generic teriparatide and levetiracetam
- US generics launch and approval for Dr Reddy’s and Lupin
- Five Chinese companies join UN’s MPP for Covid-19 medicines
- South Korean companies to make generic Bridion and COVID-19 drugs
Investigación
- Japan’s drug shortage crisis: challenges and policy solutions
- Saudi FDA drug approvals and GMP inspections: trend analysis
- Generic medications in the Lebanese community: understanding and public perception
- Community pharmacists’ understanding of generic and biosimilar drugs: Lebanon case study
General
- Crecimiento de medicamentos genéricos en Brasil y Venezuela
- EMA launches European shortages monitoring platform to tackle persistent medicine shortages
- Penetración de los medicamentos genéricos en México y Brasil
- FDA releases one-year progress report for the Generic Drug Cluster
-
Biosimilares
Novedades
- Canada approves multiple denosumab and ustekinumab biosimilars as global competition grows
- FDA approves Zimrixby (rituximab) and Garzulys (insulin aspart) biosimilars
- EMA recommends approval for biosimilar pegfilgrastim Cavoley
- FDA approves first interchangeable ranibizumab biosimilar Ranluspec
Investigación
- El HHS equipara biosimilares a genéricos y desata rechazo
- Biosimilar interchangeability: a necessary fix, but not a silver bullet
- EULAR 2025 RA guidelines streamlined as biosimilar expansion reshapes treatment sequencing
- Adopción de biosimilares en Chile: ¿Por qué se demora?
- MORE EDITORIAL SECTIONS
- Search
